Our report presents a case of a patient developing new-onset psoriasis while on treatment with IFN-β and provides an overview on the frequency and spectrum of cutaneous adverse reactions associated with IFN treatment in MS patients. Here, IFNB1 is linked to myeloid sarcoma.